HRT, breast cancer and the menopause

This study looked at whether the timing of estrogen or estrogen-progestogen therapies at the time of the menopause affected breast cancer incidence

A total of 1,129,025 postmenopausal women in the UK provided prospective information on HRT use and other factors relevant for breast cancer risk.

There were 4.05 million woman-years of follow-up during which 15,759 breast cancers occurred, with 7,107 in current users of HRT. Breast cancer incidence was increased in current HRT users but returned to that of never-users a few years after stopping treatment.

The risk for breast cancer was greater if HRT began before or soon after menopause than if it began after a longer gap. There was little or no increase in risk in women who started estrogen-only HRT 5 years or more after menopause. Risks were greater among users of estrogen-progestogen combinations than in estrogen-only users if hormonal therapy started at around the time of menopause rather than later.
Beral V, Reeves G, Bull D et al. J Natl Cancer Inst 2011; 103: 296-305

Want news like this straight to your inbox?
Sign up for our bulletins

Read these next

Breast cancer risk assessment in primary care

Breast cancer risk assessment in primary care

It is important to identify women who are at increased...

10-minute consultation: effective management of the menopause

Menopausal symptoms change and there may be a time...

Treating menopausal symptoms without HRT

Alternative options include diet and lifestyle advice....

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more